YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY). The new fund aims to provide current income by utilizing options-based strategies related to Hims & Hers Health Inc (NYSE: HIMS), a prominent consumer health and wellness business.HIMS stock is showing exceptional strength. See if it is worth your attention here.Unlike other equity ETFs, HIYY does not actually invest in Hims & Hers shares. Instead, t ...

Core Insights - PrestoDoctor, a subsidiary of Dogecoin Cash, Inc., is expanding its telemedicine services for medical cannabis evaluations to Connecticut, now operating in 19 states across the U.S. [1][4] - Since its launch in 2015, PrestoDoctor has served over 500,000 patients, establishing itself as a trusted platform for medical cannabis telehealth services [2][4]. - The Connecticut launch complies with state regulations that require certifications to be issued by licensed in-state clinicians, facilitating patient access to medical marijuana [3][6]. Company Overview - PrestoDoctor has been operational for 10 years, focusing on providing secure, patient-centered telehealth services [4][5]. - The platform offers flexible payment options, including traditional methods and select cryptocurrencies, reflecting a modern approach to healthcare solutions [4][8]. - The company emphasizes privacy and security in its telehealth workflows, consistent with its operations in other states [8]. Regulatory Compliance - The Connecticut launch aligns with state laws permitting telemedicine for medical marijuana certifications, ensuring that only licensed Connecticut professionals can issue certifications [3][6]. - Patients must complete the registration process with the Connecticut Department of Consumer Protection after receiving a certification [6].

Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States NationwideMesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company's decade-long track record of helping patients acc ...

Core Insights - PrestoDoctor, a subsidiary of Dogecoin Cash, Inc., is expanding its telemedicine services for medical cannabis evaluations to Connecticut, now operating in 19 states across the U.S. [1][4] Company Overview - Founded in 2015, PrestoDoctor has served over 500,000 patients nationwide, establishing itself as a trusted platform for medical cannabis telehealth services [2][4]. - The platform is recognized for its compliance, convenience, and patient satisfaction, connecting patients with licensed clinicians in their home states [2]. Service Expansion - The launch in Connecticut aligns with state regulations that allow telemedicine for medical marijuana certifications, requiring certifications to be issued by Connecticut-licensed healthcare professionals [3][6]. - PrestoDoctor will facilitate connections between patients and in-state clinicians, providing guidance for the medical marijuana registration process with the Connecticut Department of Consumer Protection [3][6]. Payment Options - PrestoDoctor offers flexible payment methods, including traditional payment options and select cryptocurrencies such as Dogecoin, Bitcoin, Ethereum, USD Coin, and Tether, reflecting the company's commitment to modern healthcare solutions [4][6].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1][7]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7 to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [5][6]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [5][6]. Financial Performance and Stock Impact - LifeMD reportedly faced rising customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [6]. - The situation escalated on August 5, 2025, when LifeMD announced second-quarter results that missed revenue and earnings per share estimates, leading to a drastic reduction in its full-year guidance. Following this announcement, the company's stock price dropped by over 44% [7]. Investor Actions - The lawsuit provides an opportunity for investors who incurred substantial losses during the specified period to seek recovery [8]. - Hagens Berman, the law firm investigating the claims, is looking into whether LifeMD was aware of but failed to disclose key operational issues [10].

Company Overview - LifeMD is a smaller player in the telehealth sector, positioning itself as a "direct-to-patient telehealth company" that offers a high-quality, cost-effective, and convenient way to access comprehensive virtual and in-home healthcare [1] Investment Insights - The focus on small-cap opportunities suggests a strategy aimed at finding asymmetric upside potential in the market, particularly through sustainable high dividend yields [2] - Key factors for investment consideration include insider buying, high insider ownership, a history of free cash flow growth, and substantial catalysts for turnaround [2] Analyst Position - The analyst has a beneficial long position in LifeMD shares, indicating confidence in the company's future performance [3]

Company Overview - LifeMD (NASDAQ: LFMD) is a smaller player in the telehealth sector, positioning itself as a "direct-to-patient telehealth company" that offers a high-quality, cost-effective, and convenient way to access comprehensive virtual and in-home healthcare [1] Investment Insights - The focus on small-cap opportunities suggests a strategy aimed at finding asymmetric upside potential in the market, particularly through sustainable high dividend yields [2] - Key investment criteria include insider buying, high insider ownership, a long history of free cash flow growth, and substantial catalysts for turnaround [2] Analyst Position - The analyst has a beneficial long position in LifeMD shares, indicating confidence in the company's future performance [3]

Core Insights - Caregility has secured $25.1 million in additional funding through Series A-2 and Series C rounds, bringing total external funding to $92 million [1][2] - The funding will be utilized for AI solutions, computer vision, ambient listening, and sensor-based technologies to enhance clinical workflows and support patient care [2][5] - Caregility's platform supports over 30,000 connected devices and conducts over six million virtual sessions annually across 1,500 hospitals and 75 health systems globally [3][5] Company Strategy - The modular platform includes specialty consults, operating room telehealth services, e-sitting, virtual nursing, and hospital-at-home programs [4] - The strategic investment aims to accelerate innovation and scale operations in the marketplace [4][6] - The company is positioned to redefine hospital care delivery with advanced technologies like edge-based Computer Vision AI and audio sensing for room duress detection [2][3] Market Expansion - Caregility serves customers across Asia-Pacific, the Gulf Region, the Middle East, Canada, and the US [5] - The company has expanded its international footprint by partnering with Media Plus and Yahman in Japan earlier this year [6]

The global telehealth market reached about $123.26 billion in 2024 and is expected to grow significantly, hitting $455.27 billion by 2030. This reflects a steady annual growth rate of around 24.7% starting from 2025 as more healthcare providers and patients turn to remote care options. Meanwhile, the broader healthcare sector has remained stable, with the S&P 500 Health Care Index ($SRHC) trading in a narrow range just above 1,590 points recently. Despite this overall stability, some companies are experie ...

Core Insights - Hims & Hers Health, Inc. is expanding its healthcare ecosystem through global reach, product diversification, and advanced technology integration, with plans to launch in Canada in 2026 to address the demand for affordable obesity treatments [1][7] - The company completed an $870 million convertible senior notes offering in 2025 to fund global growth, strategic acquisitions, and AI-driven personalized treatments [2][7] - Hims & Hers is entering new care categories such as testosterone therapy, menopause, sleep, fertility, and cardiovascular care, enhancing its vertically integrated ecosystem [3][7] Financial Performance - Hims & Hers shares have gained 139.2% year to date, outperforming the industry's growth of 29.7% [6] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share suggests a 122.2% improvement from 2024 [8] - The company's forward 12-month price-to-sales ratio is 4.9X, lower than the industry's average of 5.7X but higher than its three-year median of 2.5X [10] Earnings Estimates - The current quarter EPS estimate is 0.09, with a projected increase to 0.12 next quarter and 0.60 for the current year, reaching 0.80 next year [11] - Year-over-year growth estimates indicate a 50% increase for the current quarter and a 34.08% increase for the next year [11]